Login to Your Account



Error Triggers Sell-off

Vertex Falls on Corrected CF Results for Kalydeco Combo

By Catherine Shaffer
Staff Writer

Wednesday, May 30, 2012
Vertex Pharmaceuticals Inc.'s stock slid more than 10 percent Tuesday following a release of corrected clinical data for a Phase II trial of Kalydeco (ivacaftor) with VX-809, showing that only 35 percent of cystic fibrosis (CF) patients with the F508del mutation experienced an absolute improvement in lung function (FEV1) of 5 percent or more, rather than the 46 percent as reported previously.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription